Brain serotonin, psychoactive drugs, and effects on reproduction

Central Nervous System Agents in Medicinal Chemistry

Volumn 9, Issue 4, 2009, Pages 258-276

  Ayala, María Elena ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Fenfluramine; Fluoxetine; Hypothalamus; Ovary; p chloroamphetamine; Psychoactive drugs; Reproduction; Serotonin; Sexual behavior; Testis

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; AMPHETAMINE DERIVATIVE; ANDROSTANOLONE; CLOMIPRAMINE; ESTRADIOL; FENFLURAMINE; FLUOXETINE; GONADOTROPIN; IMIPRAMINE; KAINIC ACID; METHYSERGIDE; OLANZAPINE; PAROXETINE; PROGESTERONE; PROLACTIN; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN; SERTRALINE; STEROID HORMONE;

ATTENTION DEFICIT DISORDER; BULIMIA; DEPRESSION; DRUG EFFECT; DRUG MECHANISM; GONADOTROPIN RELEASE; HUMAN; HYPERACTIVITY; NARCOLEPSY; NEUROTRANSMISSION; NONHUMAN; OBESITY; OBSESSIVE COMPULSIVE DISORDER; OVULATION; REPRODUCTION; REVIEW; SEROTONIN BRAIN LEVEL; SEROTONINERGIC NERVE CELL; SEROTONINERGIC SYSTEM; SEXUAL BEHAVIOR; SEXUAL FUNCTION; SPERMATOGENESIS;

EID: 70449716054     PISSN: 18715249     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152409789630389     Document Type: Review

References (335)

1. Ersparmer, V.; Vialli, M. Ricerche sul secreto delle cellule enterocromaffini. Boll. Soc. Med. Chir. Pavia., 1937, 51, 357-363.
2. Rapport, M.M.; Green, A.A.; Page, I.H. Serum vasoconstrictor (serotonin). IV. Isolation and characterization. J. Biol. Chem., 1948, 176(3), 1243-1251.
3. Twarog, B.M.; Page, I.H. Serotonin content of some mammalian tissues and urine and a method for its determination. Am. J. Physiol., 1953, 175(1), 157-161.
4. Whitaker-Azmitia, P.M. The discovery of serotonin and its role in neuroscience. Neuropsychopharmacology, 1999, 21(2), 2S-8S.
5. Dahlstrôm, A.; Fuxe, K. Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in cell bodies of brain neurons. Acta Physiol. Scand., 1964, 232, 1-55.
6. Steinbusch, H.W. Distribution of serotonin-immunoreactive in the central nervous system of the rat-cell bodies and terminals. Neuroscience, 1981, 6(4), 557-618. (Pubitemid 11102583)
7. Törk, I. Anatomy of the serotonergic system. Ann. N. Y. Acad. Sci., 1990, 600, 9-34.
8. Azmitia, E.C.; Segal, M. An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J. Comp. Neurol., 1978, 179(3), 641-667. (Pubitemid 8372646)
9. Jacobs, B.L.; Azmitia, E.C. Structure and function of the brain serotonin system. Physiol. Rev., 1992, 72(1), 165-229.
10. McKenna, J.T.; Vertes, R.P. Collateral projections from the median raphe nucleus to the median septum and hippocampus. Brain Res. Bull., 2001, 54(6), 619-630.
11. Takeuchi, I. In Neuronal Serotonin; Osborne, N.N.; Hamon, M.; Eds.; John Wiley & Sons Ltd: New York, 1988; pp. 25-56.
12. Frankfurt, M.; Lauder, J.M.; Azmitia, E.C. The immunohistochemical localization of serotonergic neurons in the rat hypothalamus. Neurosci. Lett., 1981, 24(3), 227-232. (Pubitemid 11001674)
13. Bowker, R.M.; Westlund, K.N.; Sullivan, M.C.; Coulter, J.D. Organization of descending serotonergic projections to the spinal cord. Prog. Brain Res., 1982, 57, 239-265.
14. Chalmers, J.; Pilowsky, P. Brainstem and bulbospinal neurotransmitter systems in the control of blood pressure. J. Hypertens., 1991, 9(8), 675-694.
15. Ridet, J.L.; Geffard, M.; Privat, A. Light and electron microscopic studies of the effects of p-chloroamphetamine on the monoaminergic innervation of the rat spinal cord. J. Comp. Neurol., 1994, 343(2), 281-296.
16. O'Hearn, E.; Molliver, M.E. Organization of raphe-cortical projections in rat: a quantitative retrograde study. Brain Res. Bull., 1984, 13(6), 709-726. (Pubitemid 15090392)
17. McQuade, R.; Sharp, T. Functional mapping of dorsal and median raphe 5-hydroxytryptamine pathways in forebrain of the rat using microdialysis. J. Neurochem., 1997, 69(2), 791-796. (Pubitemid 27327983)
18. Wilson, M.A.; Ricaurte, G.A.; Molliver, M.E. Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine. Neuroscience, 1989, 28(1), 121-137.
19. Hornung, J.P. The human raphe nuclei and the serotonergic system. J. Chem. Neuroanat., 2003, 26(4), 331-343. (Pubitemid 38077156)
20. Törk, I.; Hornung, J.P. Serotoninergic innervation of the cat hippocampus. Soc. Neurosci. Abstr., 1989, 15, 1247.
21. Mamounas, L.A.; Muller, C.A.; O'Eran, E.; Molliver, M.E. Dual serotoninergic projections to forebrain in the rat: Morphologically distinct 5-HT axon terminals exhibit differential vulnerability to neurotoxic amphetamine derivates. J. Comp. Neurol., 1991, 314(3), 558-586.
22. Molliver, M.E.; Berger, U.V.; Mamounas, L.A.; Molliver, D.C., O'Hearn, E.; Wilson, M.A. Neurotoxicity of MDMA and related compounds: anatomic studies. Ann. N. Y. Acad. Sci., 1990, 600, 649-661.
23. McQuade, R.; Sharp, T. Release of cerebral 5-hydroxytryptamine evoked by electrical stimulation of the dorsal and median raphe nuclei. Effect of a neurotoxic amphetamine Neuroscience, 1995, 68(4), 1079-1088.
24. Kosofsky, B.E.; Molliver, M.E. The serotoninergic innervation of cerebral cortex different classes of axon terminals arise from dorsal and median raphe nuclei. Synapse, 1987, 1(2), 153-168.
25. Beck, S.G.; Pan, Y-Z.; Akanwa, A.C.; Kirby, L.G. Median and dorsal raphe neurons are not electrophysiologically identical. J. Neurophysiol., 2004, 91(2), 994-1005.
26. Molliver, M.E. Serotonergic neuronal systems: what their anatomic organization cells us about function. J. Clin. Psychopharmacol., 1987, 7(6), 3S-23S.
27. Morello, H.; Calagaris, L.; Haymal, B.; Taleisnik, S. Further evidence of an opposite effect of dorsal and median raphe nuclei on the proestrous surge of LH. Acta Endocrinol. (Kph)., 1990, 122(6), 696-702. (Pubitemid 20220414)
28. Morello, H.; Taleisnik, S. Changes of the release of luteinizing hormone (LH) on the day of proestrus after lesions or stimulation of the raphe nuclei in rats. Brain Res., 1985, 360(1-2), 311-317. (Pubitemid 16171028)
29. Van de Kar, L.D. Forebrain pathways mediating stress-induced renin secretion. Clin. Exp. Pharmacol. Physiol., 1996, 23(2), 166-170.
30. Trouillas, P.; Fuxe, K. In Serotonin, the Cerebellum, and Ataxia, Raven Press: New York, 1993.
31. Hornung, J.P.; Fritschy, J.M.; Tork, I. Distribution of two morphological types of serotoninergic axons in the cerebral cortex of the marmoset monkey. J. Comp. Neurol., 1990, 297(2), 165-181. (Pubitemid 20217202)
32. Trottier, S.; Evrard, B.; Vignal, J.P.; Scarabi, J.M.; Chauvel, P. The serotoninergic innervation of the cerebral cortex in man and its changes in focal cortical dysplasia. Epilepsy Res., 1996, 25(2), 79-106. (Pubitemid 26298422)
33. Descarries, L.; Watkins, K.C.; Garcia, S.; Beaudet, A. The serotonin neurons in nucleus raphe dorsalis of adult rat: a light and electron microscope autoradiographic study. J. Comp. Neurol., 1982, 207(3), 239-254. (Pubitemid 12081283)
34. Baumgarte, H.G.; Grozdanovic, A. In Serotonergic Neurons and 5-HT Receptores in the CNS; Baumgarten, H.G.; Gothert, M. Ed.; Spring Press: Germany, 2000, pp. 193-203.
35. Verbeuren, T.J. In The Peripheral Actions of 5-hydroxytryptamine; Fozars, J.R. Ed.; Oxford University Press Oxford: USA, 1994, pp. 1-25.
36. Von Bohlem, O.; Dermietzel, R. Neurotransmitters and Neuromodulators. Handbook of Receptor and Biological Effects, Wiley-Vch Verlag Gmbh & Co. Kga: Germany, 2006.
37. Frazer, A.; Hensler, G. In Basic Neurochemistry, Molecular, Cellular and Medical Aspects; Siegel, G.J.; Agranoff, B.W.; Albers, R.W.; Molinoff, P.B. Eds.; Raven Press: New York, 1999, pp 263-293.
38. Boess, F.G.; Martin, I.L. Molecular biology of 5-HT receptors. Neuropharmacology, 1994, 33(3-4), 275-317.
39. Peroutka, S.J. Molecular biology of 5-hydroxytryptamine receptor subtypes. Synapses, 1994, 18(3), 241-260.
40. Vizi, E.S. Role of high-affinity receptors and membrane transporters in nonsynaptic communication and drug action in the central nervous system. Pharmacol. Rev., 2005, 52, 63-89.
41. Derkach, V.; Surprenant, R.A.; North, R.A. 5-HT3 receptors membrane ion channels. Nature, 1989, 339(6227), 706-709.
42. Alexander, S.P.H.; Mathie, A.; Peters, J.A. 5-hydroxytryptamine (5-HT) receptors: Guide to receptors and channels. Br. J. Pharmacol., 2004, 141(1), S1-S126.
43. Saxena, P.R. Serotonin receptors: subtypes, functional responses and therapeutic relevance. Pharmacol. Ther., 1995, 66(2), 339-368.
44. Gerhardt, C.C.; Van Heerikhuizen, H. Functional characteristics of heterologously expressed 5-HT receptors. Eur. J. Pharmacol., 1997, 334(1), 1-23. (Pubitemid 27417803)
45. Fuller, R.W.; Wong, D.T. Serotonin uptake and serotonin uptake inhibition. Ann. N. Y. Acad. Sci., 1990, 600, 68-78.
46. Hoyer, D.; Hannon, J.P.; Martin, G.R. Molecular pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav., 2002, 71(4), 533-554.
47. Abraham, H.D.; Aldridge, A.M.; Gogia, P. The psychopharmacology of hallucinogens. Neuropsychopharmacology, 1996, 14(4), 285-298.
48. Kelly, A.B.; Berridge, K.C. The neuroscience of natural rewards: Relevance to additive drugs. J. Neurosci., 2002, 22(9), 3306-3311.
49. Nichols, D.E.; Oberlender, R. Structure-Activity relationships of MDMA and related compounds: A new class of psychoactive drugs. Ann. N. Y. Acad. Sci., 1990, 600, 613-624.
50. Vaswani, M.; Linda, F.K.; Ramesh, S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprensive review. Prog. Neuropsychopharmacol. Biol. Psychiatry., 2003, 27(1), 85-102. (Pubitemid 36131110)
51. Richelson, E. Pharmacology of antidepressants characteristics of the ideal antidepressant drug. Mayo Clin. Proc., 1994, 69(11), 1069-1081. (Pubitemid 24346991)
52. Chopin, P.; Briley, M. The effect of compounds that modify 5-HT neurotransmission. Trends Pharmacol. Sci., 1987, 8, 383-388. (Pubitemid 18084589)
53. Roth, B.L; Hanizavareh, S.M.; Blum, A.E. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology (Berl), 2004, 174(1), 17-24.
54. Warneke, L. Psychoestimulants in psychiatry. Can. J. Psychiatry, 1990, 35(1), 3-10.
55. Axt, K.J.; Molliver, M.E. Immunocytochemical evidence for methamphetamine-induced serotonergic axon loss in the rat brain. Synapse, 1991, 9(4), 302-313.
56. Clineschmidt, B.V.; Zacchel, A.G.; Totaro, J.A.; Pflueger, A.B.; McGuffin, J.C.; Wishousky, T.I. Fenfluramine and brain serotonin. Ann. N. Y. Acad. Sci., 1978, 305, 222-241.
57. Jayanthi, L.D.; Ramamoorthy, S. Regulation of monoamines transporter: Influence of psychoestimulants and therapeutic antidepressants. AAPS J., 2005, 7(3), E728-E738.
58. Sanders-Bush, E.; Massari, V.J. Actions of drugs that deplete serotonin. Fed. Proc., 1977, 36(8), 2149-2153.
59. White, K.J.; Walline, C.C.; Barker, E.L. Serotonin transporters: implications for antidepressant drug development. AAPS J., 2005, 7(2), E421-E433.
60. Ricaurte, G.A.; Forno, L.S.; Wilson, M.A.; DeLanney, L.E.; Irwin, I.; Molliver, M.E.; Langston, J.W. (±)3,4-methylenedioxymethamphetamine (MDMA) selectively damages central serotoninergic neurons in nonhuman primates. J. Am. Med. Assoc., 1988, 260(1), 51-55.
61. Berger, U.V.; Gu, X.F.; Azmitia, E.C. The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. Eur. J. Pharmacol., 1992, 215(2-3), 153-160.
62. Fuller, R.W. Effects of p-chloroamphetamine on brain serotonin neurons. Neurochem. Res., 1992, 17(5), 449-456.
63. Fuller, R.W. Structure-activity relationships among the halogenated amphetamines. Ann. N. Y. Acad. Sci., 1978, 305, 147-159.
64. Sekerke, H.J.; Smith, H.E.; Bushing, J.A.; Sanders-Bush, E. Correlation between brain levels and biochemical effects of the optical isomers of p-chloroamphetamine. J. Pharmacol. Exp. Ther., 1975, 193(3), 835-844.
65. Robertson, D.W.; Krushinski, J.H.; Fuller, R.W.; Leander, J.D. Absolute configurations and pharmacological activities of the optical isomers of fluoxetine, a selective serotonin-uptake inhibitors. J. Med. Chem., 1988, 31(7), 1412-1417.
66. Wong, D.T.; Fuller, R.W.; Robertson, D.W. Fluoxetine and its two enantiomers as selective serotonin uptake inhibitors. Acta Pharm. Nord., 1990, 2(3), 171-180.
67. Wong, D.T.; Threlkeld, P.G.; Robertson, D.W. Affinities of fluoxetine, its enantiomers, and other inhibitors of serotonin uptake for subtypes of serotonin receptors. Neuropsychopharmacology, 1991, 5(1), 43-47.
68. Phillips, S.; Brent, J.; Kuling, K.; Heiligenstein, J.; Birkett, M. Fluoxetine versus tricyclic antidepressants: A propespective multicenter study of antidepressants drug overdoses. The antidepressants study group. J. Emerg. Med., 1997, 15(4), 439-445.
69. Stahl, S.M. Basic psychopharmacology of antidepressants, part I: Antidepressants have seven distinct mechanisms of action. J. Clin. Psychiatry, 1998, 59(4), 5-14.
70. Dawson, L.A.; Bromidge, S.M. 5-HT1 receptor augmentation strategies as enhanced efficacy: therapeutics for psychiatric disorders. Curr. Top. Med. Chem., 2008, 8(12), 1008-1023.
71. Weltzin, T.E.; Fernstrom, M.H.; Kaye, W.H. Serotonin and bulimia nervosa. Nutr. Rev., 1994, 52(12), 399-408.
72. Leibowitz, S.F.; Alexander, J.T. Hypothalamic serotonin in control eating behavior, meal size and body weight. Biol. Pschyatry, 1998, 44(9), 851-864.
73. Halford., J.C.; Harrold, J.A.; Lawton, C.L.; Blundell, J.E. Serotonin (5-HT) drugs. Effects on appetite expression and use for the treatment of obesity. Curr. Drug Targets, 2005, 6(2), 201-213.
74. Leibowitz, S.F.; Alexander, J.T.; Cheung, W.K.; Weiss, G.F. Effects of serotonin and the serotonin blocker metergoline on meal patterns and macronutrient selection. Pharmacol. Biochem. Behav., 1993, 45(1), 185-194. (Pubitemid 23124378)
75. Nichols, D.E. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J. Psychoactive Drugs, 1986, 18(4), 305-313.
76. Cunha-Oliveira.T.; Rego, A.C.; Oliveira, C.R. Cellular and molecular mechanisms involved in the neurotoxicity of opioid and psychostimulant drugs. Brain Res. Rev., 2008, 58(1), 192-208.
77. Shulgin, A.T. The background and chemistry of MDMA. J. Psychoactive Drugs, 1986, 18(4), 291-304.
78. Cano-Muñoz, J.L.; Montejo-Iglesias, M.L.; Yánez-Saez, R.M.; Gálvez-Borrero, I.M. Possible serotonin syndrome following the combined administration of clomipramine and alprazolam. J. Clin. Psychiatry, 1995, 56(3), 122.
79. Gillman, P.K. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br. J. Pharmacol., 2007, 151(6), 737-748.
80. Otte, E.; Birkenhager, T.K.; van Den, Broek WW. Fatal interaction between tranylcipromine and imipramine. Eur. Psychiatry, 2003, 18(5), 264-265.
81. Tao, R.; Fray, A.; Aspley, S.; Brammer, R.; Heal, D.; Auerbach, S. Effects on serotonin in rat hypothalamus of D-fenfluramine, aminorex, phentermine and fluoxetine. Eur. J. Pharmacol., 2002, 445(1-2), 69-81. (Pubitemid 34628434)
82. Fuller, R.W. Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis. Life Sci., 1994, 55(3), 163-167. (Pubitemid 24187116)
83. Kuhs, H.; Schlake, H.P.; Rolf, L.H.; Rudolf, G.A. Relationship between parameters of serotonin transport and antidepressant plasma levels of therapeutic response in depressive patients treated with paroxetine and amitriptyline. Acta Psychiatr. Scand., 1992, 85(5), 364-369.
84. Lundmark, J.; Scheel T.I.; Thomsen, I.S.; Fjord-Larsen, T.; Manniche, P.M.; Mengel, H.; Moller-Nielsen, E.M.; Pauser, H.; Walinder, J. Pharmacokinetic and antidepressant effects in the elderly. Acta Psychiatr. Scand., 1989, 80(350), 76-80.
85. Fuller, R.W.; Snoddy, H.D.; Robertson, D.W. Mechanisms of effects of d-fenfluramine on brain serotonin metabolism in rats: uptake inhibition versus release. Pharmacol. Biochem. Behav., 1988, 30(3), 715-721.
86. Baumann, M.H.; Ayestas, M.A.; Dersch, C.M.; Partilla, J.S.; Rothman, R.B. Serotonin transporters, serotonin release, and mechanism of fenfluramine neurotoxicity. Ann. N. Y. Acad. Sci., 2000, 914, 172-186.
87. Appel, N.M.; Contrera, J.F.; DeSouza, E.B. Fenfluramine selectively and differentially decreases the density of serotoninergic nerve terminals in rat brain: Evidence from immunocytochemical studies. J. Pharmacol. Exp. Ther., 1989, 249(3), 928-943.
88. Appel, N.M.; Mitchell, W.M.; Contrera, J.F.; De Souza, E.B. Effects of high-dose fenfluramine treatment on monoamine uptake sites in rat brain: Assessment using quantitative autoradiography. Synapse, 1990, 6(1), 33-44.
89. McCann, U.D.; Yuan, J.; Hatzidimitriou, G.; Ricaurte G.A. Selective serotonin reuptake inhibitors dissociate fenfluramine's anoretic and neurotoxic effects: Importance of dose, species and drug. J. Pharmacol. Exp. Ther., 1997, 281(3), 1487-1498.
90. Schuster, C.R.; Lewis, M.; Seiden, L. Fenfluramine: neurotoxicity. Psychopharmacol. Bull., 1986, 22(1), 148-151.
91. Johnson, M.P.; Nichols, D.E. Comparative serotonin neurotoxicity of the stereoisomers of fenfluramine and norfenfluramine. Pharmacol. Biochem. Behav., 1990, 36(1), 105-109.
92. Su., Y.A.; Si, T.M.; Shou, D.F.; Gou, C.M.; Wang, X.D.; Yang, Y.; Shu, L.; Liang, J. H. Risperidone attenuates MK-801 induced hyperlocomotion in mice via the blockade of serotonin 5-HT 2A/2C receptors. Eur. J. Pharmacol., 2007, 564(1-3), 123-130
93. Uchida, S.; Kato, Y.; Hirano, K.; Kagawa, Y.; Yamada, S. Brain neurotransmitters receptor-biding characteristics in rats after oral administration of haloperidol, risperidone and holanzapine. Life Sci., 2007, 80(17), 1635-1640. (Pubitemid 46412363)
94. Steranka, L.R.; Sanders-Bush, E. Long term reduction brain serotonin by p-chloroamphetamine. Effects of inducers and inhibitors of drug metabolism. J. Pharmacol. Exp. Ther., 1978, 206, 460-467.
95. Lorez, H.P.; Saner, A.; Richards, J.G. Evidence against a neurotoxic action of halogenated amphetamines on serotoninergic B9 cells. A morphometric fluorescence histochemical study. Brain Res., 1978, 146(1), 188-194.
96. Ricaurte, G.A.; Bryan, G.; Stratuss, L.; Schuster, C. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science, 1985, 229(4717), 986-988.
97. Sanders-Bush, E.; Steranka, L.R. Immediate and long-term effects of p-chloroamphetamine on brain amines. Ann. N. Y. Acad. Sci., 1978, 305, 208-221.
98. Datla, K.P.; Curzon, G. Effect of p-chlorophenylalanine at moderate dosage on 5-HT and 5-HIAA concentrations in brain regions of control and p-chloroamphetamine treated rat. Neuropharmacology, 1996, 35(3), 315-320.
99. Nakagawa, T.; Kaneko, S. Neuropsychotoxicity of abused drugs: molecular and neural mechanisms of neuropsychotoxicity induced by methamphetamine, 3.4-methylenedioxymethamphetamine (ecstasy), and 5-methoxy-N, N-diisopropyltryptamine (foxy). J. Pharmacol. Sci., 2008, 106(1), 2-8. (Pubitemid 351159062)
100. Mamounas, L.A.; Molliver, M.E. Evidence for dual serotoninergic projections to neocortex: axons from the dorsal and medial raphe nuclei are differentially vulnerable to the neurotoxin pchloroamphetamine (PCA). Exp. Neurol., 1988, 102(1), 23-36.
101. Rudnick, G.; Wall, S.C. p-chloroamphetamine induces serotonin release through serotonin transporters. Biochemistry, 1992, 31(29), 6710-6718.
102. Cole, J.C.; Summall, H.R. The pre-clinical behavioral pharmacology of 3,4-methylenedioxymethamphetamine (MDMA). Neurosci. Biobehav. Rev., 2003, 27(3), 199-217.
103. Stone, D.M.; Stahl, D.C.; Hanson, G.R.; Gibb, J.W. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic system in the rat brain. Eur. J. Pharmacol., 1986, 128(1-2), 41-48.
104. Colado, M.I.; O'Shea, E.; Granados, R.; Murray, T.K.; Green, A.R. In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ("ecstasy") and p-chloroamphetamine but not the degeneration following fenfluramine. Br. J. Pharmacol., 1997, 121(5), 889-900.
105. Ricaurte, G.A.; Yuan, J.; McCann, U.D. (+/-)3,4- Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology, 2000, 42(1), 5-10. (Pubitemid 30436310)
106. De Silva, D.J.; French, S.J.; Cheung, N.Y.; Swinson, A.K.; Bendotti, C.; Rattray, M. Rat brain serotonin neurons that express neuronal nitric oxide synthase have increased sensitivity to the substituted amphetamine serotonin toxins 3,4-methylenedioxymethamphetamine and p-chloroamphetamine. Neuroscience, 2005, 134(4), 1363-1375. (Pubitemid 41207384)
107. Shankaran, M.; Gudeisky, G.A. Effect of 3,4-methylenedioxymethamphetamine (MDMA) on hippocampal dopamine and serotonin. Pharmacol. Biochem. Behav., 1998, 61(4), 361-366.
108. Sprague, J.E.; Everman, S.L.; Nichols, D.E. An integrated hypothesis for the serotoninergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology, 1998, 19, 427-441.
109. Quinton, M.S.; Yamamoto, B.K. Causes and consequences of methamphetamine and MDMA toxicity. AAPS J., 2006, 8(2), E337-E345.
110. 2A receptors in rat and human brain. J. Neuropsychopharmacology, 2002, 26(3), 387-396.
111. McCann, U.D.; Mertl, M.; Eligulashvili, V.; Ricaurte, G.A. Cognitive performance in (+/-) 3,4-methylenedioxy-methamphetamine (MDAM, "ecstasy") users: a controlled study. Psychopharmacology, 1999, 143(4), 417-425.
112. McCann, U.D.; Szabo, Z.; Vranesic, M.; Seckin, E.; Wand, G.; Duval, A.; Dannals, R.F.; Ricaurte, G.A. Quantitative positron emission tomography studies of the serotonin transporter in humans previously treated with the appetite suppressants fenfluramine or dexfenfluramine. Mol. Imaging Biol., 2007, 9(3), 151-157.
113. Green, A.R.; Mechan, A.O.; Elliot, J.M.; O'Shea E.; Colado, M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol. Rev., 2003, 55(3), 463-508.
114. Schmidt, C.J.; Gibb, J.W. Role of the serotonin uptake carrier in the neurochemical response to methamphetamine: effects of citalopram and chlorimipramine. Neurochem. Res., 1985, 10(5), 637-648. (Pubitemid 15087643)
115. Rothman, R.B.; Jayanthi, S.; Wang, X.; Dersch, C.M.; Cadet, J.L.; Prisinzano, T.; Rice, K. C.; Baumann, M.H. High-dose fenfluramine administration decreases serotonin transporter binding, but not serotonin transporter protein levels, in rat forebrain. Synapse, 2003, 50(3), 233-239.
116. Kleven, M.S.; Seiden, L.S. D-,L- and DL-fenfluramine cause long-lasting depletions of serotonin in rat brain. Brain Res., 1989, 505, 351-353.
117. Lyles, J.; Cadet, J.L. Methylenedioxymethamphetamine (MDAM, Ecstasy) neurotoxicity: cellular and molecular mechanisms. Brain Res. Brain Res. Rev., 2003, 42(2), 155-168.
118. Commins, D.L.; Axt, K.J.; Vosmer, G.; Seiden, L.S. Endogenously produces 5,6-dihidroxytryptamine may mediate the neurotoxic effects of para-chloroamphetamine. Brain Res., 1987, 419(1-2), 253-261.
119. Berger, U.V.; Grzanna, R.; Molliver, M.E. The neurotoxic effects of p-chloroamphetamine in rat brain are blocked by prior depletion of serotonin. Brain Res., 1992, 578(1-2), 177-185.
120. 3H-p chloroamphetamine. Neuropharmacology, 1977, 16(1), 17-24.
121. Sherman, A.D.; Gál, E.M. Mass-spectrographic evidence of the convertion of p-chloroamphetamine to 3,4-dimethoxyamphetamine. Psychopharmacol. Commun., 1976, 2(5-6), 421-427.
122. Hiramatsu, M.; Kumagai, Y.; Unger, S.E.; Cho, A.K. Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. J. Pharmacol. Exp. Ther., 1990, 254(2), 521-527.
123. Lim, H.K.; Foltz, R.L. Ion trap tandem mass spectrometric evidence for the metabolism of 3,4-(methylenedioxy) methamphetamine to the potent neurotoxins 2,4,5-trihydroxymephetamphetamine and 2,4,5-trihydroxyamphetamine. Chem. Res. Toxicol., 1991, 4(6), 626-632.
124. Maurer, H.H.; Bickeboeller-Friedrich, J.; Kraemer, T.; Peters, F.T. Toxicokinetics and analytic toxicology of amphetamine-derived designer drugs ('Ecstasy'). Toxicol. Lett., 2000, 112-113, 133-142.
125. Stone, D.M.; Johnson, M.; Hanson, G.R.; Gibb, J. W. Role of endogenous dopamine in the central serotoninergic deficits induced by 3,4- methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther., 1988, 247(1), 79-87.
126. McCann, U.D.; Szabo, Z.; Vranesic, M.; Palermo, M.; Mathews, W.B.; Ravert, H.T.; Dannals, R.F.; Ricaurte, G.A. Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance. Psychopharmacology (Berl), 2008, 200(3), 439-450.
127. García-Osta, A.; Frechilla, D.; Del Rio, J. Effect of pchloroamphetamine on 5-HT1A and 5-HT7 serotonin receptor expression in rat brain. J. Neurochem., 2000, 74(5), 1790-1797. (Pubitemid 30217633)
128. Benfield, P.; Heel, R.C.; Lewis, S.P. Fluoxetine, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in depressive illness. Drugs, 1986, 32(6), 481-508. (Pubitemid 17190279)
129. Rutter, J.J.; Auerbach, S.B. Acute uptake inhibition increases extracellular serotonin in the rat forebrain. J. Pharmacol. Exp. Ther., 1993, 265(3), 1319-1324.
130. Stark, P.; Fuller, R.W.; Wong, D.T. The pharmacological profile of fluoxetine. J. Clin. Psychiatry, 1985, 46(3-2), 7-13.
131. Wong, D.T.; Bymaster, F.P.; Reid, L.R.; Fuller, R.W.; Perry, K.W. Inhibition of serotonin uptake by optical isomers of fluoxetine. Drug Dev. Res., 1985, 6(4), 397-403.
132. Fuller, R.W.; Perry, K.W.; Molloy, B.B. Effect of an uptake inhibitor on serotonin metabolism in rat brain: studies with 3-(ptrifluoromethylphenoxy)-N- methyl-3-phenylpropylamine (Lilly 110140). Life Sci., 1974, 15(6), 1161-1171.
133. Fuller, R.W.; Wong, D.T.; Robertson, D.W. Fluoxetine, a selective inhibitor of serotonin uptake. Med. Res. Rev., 1991, 11(1), 17-34.
134. Hutson, P.H.; Sarna, G.S.; O'Connell, M.T.; Curzon, G. Hippocampal 5-HT synthesis and release in vivo is decreased by infusion of 8-OH-DPAT into the nucleus raphe dorsalis. Neurosci. Lett., 1989, 100(1-3), 276-280. (Pubitemid 19128188)
135. Riad, M.; Garcia, S.; Watkins, K.C.; Jodoin, N.; Doucet, E.; Langlois, X., Mestikawy, S.; Hamon, M.; Descarries, L. Somatodendritic localization of 5-HT1A and preterminal axonal localization of 5-HT1B serotonin receptors in adult rat brain. J. Comp. Neurol., 2000, 417(2), 181-194. (Pubitemid 30038263)
136. Corradetti, R.; Le Poul, E.; Laaris, N.; Hamon, M.; Lanfumey, L. Electrophysiological effects of N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)- N-(2-pyridinyl) cyclohexane carboxamide (WAY 100635) on dorsal raphe serotonergic neurons and CA1 hippocampal pyramidal cells in vitro. J. Pharm. Exp. Ther., 1996, 278(2), 679-688. (Pubitemid 27167034)
137. Rutter, J.J.; Gundlah, C.; Auerbach, S.B. Systemic uptake inhibition decreases serotonin release via somatodendritic receptor activation. Synapse, 1995, 20(3), 225-233.
138. Czachura, J.F.; Rasmussen, K. Effects of acute and chronic administration of fluoxetine on the activity of serotoninergic neuron on the dorsal raphe nucleus of the rat. Naunyn Schmiedebergs Arch. Pharmacol., 2000, 362(3), 266-275. (Pubitemid 30679082)
139. Jennes, L.; Conn, P.M. Gonadotropin-releasing hormone and its receptor in rat brain. Front. Neuroendocrinl., 1994, 15(1), 51-77. (Pubitemid 24213566)
140. Silverman, A.J.; Liune, I.; Witkin, J.W. In The Physiology of Reproduction; Knobil, E.; Neill J.D. Eds.; Raven Press: New York, 1994; Vol.2, pp.1683-1709.
141. Krsmanovic, L.Z.; Martínez-Fuentes, A.J.; Arora, K.K.; Mores, N.; Tomić, M.; Stojilkovic, S.S.; Catt, K.J. Local regulation of gonadotrophin function by pituitary gonadotropin-releasing hormone. Endocrinology, 2000, 141(3), 1187-1195. (Pubitemid 32260462)
142. Marshall, J.C.; Kelch, R.P. Gonadotropin-releasing hormone: role of pulsatile secretion in the regulation of reproduction. N. Engl. J. Med., 1986, 315(23), 1459-1468. (Pubitemid 17051707)
143. Arias, P.; Zwarcfarb, B.; de Rondina, D.C.; Carbone, S.; Sverdlik, R.; Moguilevsky, J.A. In vivo and in vitro studies on the effect of the serotoninergic system on luteinizing hormone and luteinizing hormone-releasing hormone secretion in prepubertal and peripuberal female rats. Brain Res., 1990, 523(1), 57-61.
144. Kordon, C.; Drouvas, S.V.; Martínez de la Escalera, E.G.; Weiner, R.I. In The Physiology of Reproduction. Knobil, E.; Neill, J.D. Eds.; Raven Press: New York, 1994; Vol.I, pp.1621-1681.
145. Smith, J.M.; Jennes, L. Neural signals that regulate GnRH neurons directly during the oestrous cycle. Reproduction, 2001, 122(1), 1-10. (Pubitemid 32677143)
146. Moguilevsky, J.A.; Wuttke, W. Changes in the control of gonadotrophin secretion by neurotransmitters during sexual development in rats. Exp. Clin. Endocirnol. Diabetes, 2001, 109(4), 188-195. (Pubitemid 32577685)
147. Brann, D.W.; Mahesh, V.B. Endogenous excitatory amino acid involvement in the preovulatory and steroid-induced surge of gonadotropins in the female rat. Endocrinology, 1991, 128(3), 1541-1547.
148. Feleder, C.; Ginzburg, M.; Wuttke, W.; Moguilevsky, J.A.; Arias, P. GABAergic activation inhibits the hypothalamic-pituitary-ovarian axis and sexual development in the immature female rat. Associated changes in hypothalamic glutamatergic and taurinergic systems. Brain Res. Dev. Brain Res., 1999, 116(2), 151-157.
149. Fernández-Fernandez, R.; Aguilar, M.; Tena-Sempere, M; Pinilla, L. Effects of polypeptide YY3-36 upon luteinizing hormone-releasing and gonadotropin secretion in prepubertal rats: in vivo and in vitro studies. Endocrinology, 2005, 146(3), 1403-1410. (Pubitemid 40289329)
150. Maekawa, F.; Tsukahara, S.; Tsukamura, H.; Maeda, K-I.; Yamanouchi, K. Prevention of inhibitory effect of dorsal raphe nucleus lesions on ovulation and LH surge by 5-HT 2A/2C receptor agonists in female rats. Neurosci. Res., 1999, 35(4), 291-298.
151. Ayala, M.E.; Rosas, P.; Domínguez, R. Different effects of unilateral and bilateral lesions of the dorsal raphe nucleus on puberty and first ovulation. Brain Res. Bull., 1994, 34(1), 27-30. (Pubitemid 24099722)
152. Ayala, M.E.; Monroy, J.; Molares, L.; Castro, M.E.; Domínguez, R., Effects of the lesion in the dorsal raphe nucleus performed during the juvenile period of the female rat, on puberty. Brain Res. Bull., 1998, 47(3), 211-218. (Pubitemid 29060816)
153. Monroy, J.; Ayala, M.E.; Chavira, R.; Damián-Matsumura, P.; Domínguez, R. Comparative effects on injecting 5,6-dihydroxytryptamine in the dorsal or medial raphe nuclei on rat puberty. Brain Res. Bull., 2003, 60(3), 307-315. (Pubitemid 36561551)
154. Morello, H.; Caligaris, L.; Haymal, B.; Taleisnik, S. Inhibition of proestrous LH surge and ovulation in rats evoked by stimulation of the medial raphe nucleus involves a GABA-mediated mechanism. Neuroendocrinology, 1989, 50(1), 81-87.
155. Anselmo-Franci, J.A.; Rocha-Barrios, V.M.; Franci, C.R.; McCann, S.M. Locus ceruleus lesions block pulsatile release in ovariectomized rats. Brain Res., 1999, 833(1), 86-99.
156. Edwards, H.E.; Burnham, W.M.; Ng MM, Asa, S.; MacLusky, N.J. Limbic seizures alter reproductive function in the female rat. Epilepsia, 1999, 40(10), 1370-1377.
157. Kerdelué, B.; Bojda, F.; Lesiure, P.; Pasqualini, C.; El Abed, A.; Lenoir, V.; Douillet, P.; Chiuch, M.C.; Palkovits, M. Median eminence dopamine and serotonin neural activity. Neuroendocrinology, 1989, 49(2), 176-180.
158. Moguilevsky, J.A.; Faigón, M.R.; Scacchi, P.; Szwarcfarb, B. Effect of serotoninergic system on luteinizing hormone secretion in prepubertal female rat. Neuroendocrinology, 1985, 40(2), 135-138. (Pubitemid 15154184)
159. Lacau-Mengido, I.M.; Libertun, C.; Becú-Villalobos, D. Different serotonin receptor types participate in 5-hydroxytryptophan-induced gonadotropins and prolactin release in the female infantile rat. Neuroendocrinology, 1996, 63(5), 415-421. (Pubitemid 26138045)
160. Villar, J.M.; Chiocchio, S.R.; Tramezzani, J.H. Origin and termination of dorsal raphe median eminence projections. Brain Res., 1984, 324(1), 165-170.
161. Justo, S.N.; Rossano, G.L.; Szwarcfarb, B.; Rubio, M.C.; Moguilevsky, J.A. Effects of serotoninergic system of FSH secretion in male and female rats: Evidence for stimulatory and inhibitory actions. Neuroendocrinology, 1989, 50(4), 382-386.
162. Becú-Villalobos, D.; Lacau-Mengido, I.M.; Libertun, C. Developmental changes in FSH secretion induced by 5-hydroxytryptophan, naloxone and haloperidol in male and female rats. Brain Res. Dev. Brain Res., 1989, 47(2), 181-186. (Pubitemid 19149863)
163. Collu, R.; Jequier, J.C.; Letarte, J.; Leboeuf, G.; Ducharme, J.R. Endocrinology effects of brain serotonin depletion by 5,6-dihydroxytryptamine in prepubertal male rats. Neuroendocrinology, 1974, 14(3), 139-150.
164. Naumenko, E.V.; Shishkina, G.T. Hypothalamic serotoninergic receptors in negative feed-back regulation of pituitary-testicular axis in rats. Endocrinol. Exp., 1980, 14(3), 207-213.
165. Shishkina, G.T.; Dygalo, N.N. Role of the serotoninergic system in the
166. Shishkina, G.T.; Borodin, P.M. Involvement of brain serotonin in regulation of sexual maturity in male rats. Neurosci. Behav. Physiol., 1989, 19(2), 145-149.
167. Aragón, M.A.; Ayala, M.E.; Marín, M.; Aviléz, A.; Damián-Matsumura, P; Domínguez, R. Serotoninergic system blockage in the prepubertal rat inhibits spermatogenesis development. Reproduction, 2005, 129(6), 717-727. (Pubitemid 40879599)
168. Hery, M.; Laplante, E.; Kordon, C. Participation of serotonin in the phasic release of LH. Evidence from pharmacological experiments. Endocrinology, 1976, 99(2), 496-503.
169. Labhsetwar, A.P.; Role of monoamines in ovulation: Evidence for a serotoninergic pathways for inhibition of spontaneous ovulation. J. Endocrinol., 1972, 54(2), 269-275.
170. Wilson, C.A.; Horth, C.E.; McNeilly, A.; McDonald, P.C. Effect of serotonin and progesterone on induced ovulation in immature rats. J. Endocrinol., 1975, 64(2), 337-347.
171. Moguilevsky, J.A.; Faigón, M.R.; Scacchi, P.; Szwarcfarb, B. Role of sexual differentiation of the hypothalamus in the differential effect of the serotoninergic system on LH in prepubertal male and female rats. Neuroendocrinology, 1987, 45(4), 274-277. (Pubitemid 17040657)
172. Ayala, M.E.; Rosas, P.; Domínguez, R. Effects of serotoninergic blockade provoked at different ages on spontaneous and induced puberty in the female rat. Med. Sci. Res., 1993, 21, 509-511. (Pubitemid 23214901)
173. Kim, M.A.; Lee, H.S.; Lee, B.Y.; Watherhouse B.D. Reciprocal connections between subdivisions of the dorsal raphe and the nuclear core of the locus coeruleus in the rat. Brain Res., 2004, 1026(1), 56-67.
174. Luppi, P.H.; Aston-Jones, G.; Akaoka, H.; Chouvert G.; Jouvet, M. Afferent projections to the rat locus coeruleus demonstrated by retrograde and anterograde tracing with cholera-toxin B subunit and PHA-L. Neuroscience, 1995, 65(1), 119-160.
175. Peyron, C.; Luppi, P.H.; Fort, P.; Rampon, C.; Jouvet, M. Lower brainstem catecholamine afferents to the rat dorsal raphe nucleus. J. Comp. Neurol., 1996, 364(3), 402-413. (Pubitemid 26039427)
176. Szabo, S.T.; Blier, P. Functional and pharmacological characterization of the modulatory role of serotonina on the firing activity of locus coeruleus morepinephrine neurons. Brain Res., 2001, 922(1), 9-20.
177. Rioja, J.; Santín, L.J.; López-Barroso, D.; Doña, A.; Ulzurrum, A.E.; Aguirre, J.A. 5-HT1A receptor activation counteracted the effect of acute immobilization of noradrenergic neurons in the rat locus coeruleus. Neurosci. Lett., 2007, 412(1), 84-88. (Pubitemid 46038554)
178. Vandermaelen, C.P.; Aghajanian, G.K. Electrophysiological and pharmacological characterization of serotonergic dorsal raphe neurons record extracellulary and intracellulary in rat brain slices. Brain Res., 1983, 289(1-2), 109-119.
179. Anselmo-Franci, J.A.; Franci, C.R.; Krulich, L; Antunes-Rodríguez, J.; McCann S.M. Locus coeruleus lesions decrease norepinephrine input into the medial pre-optic area and medial basal hypothalamus and block the LH, FSH and prolactin preovulatory surge. Brain Res., 1997, 767(2), 289-296.
180. Morello, H.; Taleisnik, S. The inhibition of proestrous LH surge and ovulation in rats bearing lesions of the dorsal raphe nucleus is mediated by locus coeruleus. Brain Res., 1988, 440(2), 227-231. (Pubitemid 18049219)
181. Gnessi, L.; Fabbri, A.; Spera, G. Gonadal peptides as mediators of developmental and functional control of the testis: An integrated system with hormones and local environment. Endocr. Rev., 1997, 18(4), 541-609. (Pubitemid 27349556)
182. O'Donnell, L.; Robertson, K.M.; Jones, M.E.; Simpson, E.R. Endocrine Rev., 2001, 22(3), 289-318.
183. Sharpe, R.M. In The Phisyology of Reproduction, Knobil, E.; Neill, J.D., Eds.; Raven Press: New York, 1994; Vol 2, pp. 1363-1434.
184. Dominguez, R.; Appeltauer, L.C.; Benedetti, W.L.; Griño, E.; Sas, J. Efecto de lesiones de la formación reticulada mesencefálica sobre la gonada de la rata blanca macho. Rev. Argent. Endocrinol. Metab., 1963, 9, 60-70.
185. Yamamoto, Y.; Yamamoto, K.; Hayase, T.; Abiru, H.; Shiota, K.; Mori, Ch. Methamphetamine induces apoptosis in seminiferous tubules in male mice testis. Toxicol. Appl. Pharmacol., 2002, 178(3), 155-160.
186. Tinajero, J.C.; Fabbri, A.; Ciocca, D.R.; Dufau, M.L. Serotonin secretion from rat leydig cells. Endocrinology, 1993, 133(6), 3026-3029.
187. Collin, O.; Damber, J.E.; Bergh, A. 5-hydroxytriptmine a local regulator of testicular blood flow and vasomotion in rats. J. Reprod. Fertil., 1996, 106(1), 17-22. (Pubitemid 126686923)
188. Aguilar, R.; Antón, F.; Bellido, C; Aguilar, E.; Gaytan, F. Testicular serotonin is related to mast cells but not to leydig cells in the rat. J. Endocrinol., 1995, 146(1), 15-21.
189. Piner, J.; Sutherland, M.; Millar, M.; Turner, K.; Newll, D.; Sharpe, R.M. Changes in vascular dynamics of the adult rat testis leading to transient accumulation of seminiferous tubule fluid after administration of a novel 5-hydroxytryptamine (5-HT) agonist. Reprod. Toxicol., 2002, 16(2), 141-150.
190. Tsai, S.C.; Chiao. Y.C.; Lu, C.C.; Doong, M.L.; Chen, Y.H.; Shih, H.C.; Liaw, C.; Wang, S.W.; Wang, P.S. Inhibition by amphetamine of testosterone secretion through a mechanism involving and increase of cyclic AMP production in rats testes. Br. J. Pharmacol., 1996, 118(4), 984-988.
191. Tsai, S.C.; Chen, J.J.; Chiao, Y.C.; Lu, C.C.; Lin, H.; Yeh, J.Y.; Lo. M.J., Kau, M.M.; Wang, S.W.; Wang, P.S. The role of cyclic AMP production, calcium channel activation and enzyme activities in the inhibition of testosterone secretion by amphetamine. Br. J. Pharmacol., 1997, 122(5), 949-955.
192. Chen, L.Y.; Huang, Y.L.; Liu, M.Y.; Leu, S.F.; Huang, B.M. Effects of amphetamine on steroidogenesis in MA-10 mouse leydig tumor cells. Life Sci., 2003, 72(17), 1983-1995.
193. Gerendai, I.; Csaba, Z.; Vokó, Z.; Csernus, V. Involvement of a direct neural mechanism in the control of gonadal functions. J. Steroid. Biochem. Mol. Biol., 1995, 53(1-5), 299-305.
194. Banczerowski, P.; Csaba, Z.; Csernus, V.; Gerendai, I. The effect of callosotomy on testicular steroidogenesis in hemiorchidectomized rats: a pituitary-independent regulatory mechanism. Brain Res. Bull., 2000, 53(2), 227-232. (Pubitemid 30759068)
195. Banczerowski, P.; Csaba, Z.; Csernus, V.; Gerendai, I. Lesion of the amygdala on the right and left side suppresses testosterone secretion but only left-side intervention decreases serum luteinizing hormone level. J. Endocrinol. Invest., 2003, 26(5), 429-434.
196. Lepore, G.; Sedda, M; Gerendai, I.; Csernus, V.; Gadau, S.; Manca, P.; Chisu, V.; Farina, V. Rigth occipital cortex suppresses male rat testosterone secretion by a pituitary-independent mechanism. Neuro Endocrinol. Lett., 2006, 27(4), 501-505. (Pubitemid 46043608)
197. Selvage, D.J.; Parsons, L.; Rivier, C. Role played by brainstem neurons in regulating testosterone secretion via a direct neural pathway between the hypothalamus and the testes. Endocrinology, 2006, 147(6), 3070-3075. (Pubitemid 43764642)
198. James, P.; Rivier, C.; Lee, S. Presence of corticotrophin-releasing factor and/or tyrosine hydroxylase in cells of a neural brain-testicular pathway that are labelled by a transganglionic tracer. J. Neuroendocrinol., 2008, 20(2), 173-181. (Pubitemid 351147004)
199. Selvage, D.J.; Rivier, C. Importance of the paraventricular nucleus of the hypothalamus as a component of a neural pathway between the brain and the testes that modulates testosterone secretion independently of the pituitary. Endocrinology, 2003, 144(2), 594-598. (Pubitemid 36205232)
200. Vertes, R.P. A PHA-L analysis of ascending projections of the dorsal raphe nucleus in the rat. J. Comp. Neurol., 1991, 313(4), 643-668.
201. Vertes, R.P.; Kocsis, B. Projections of the dorsal raphe nucleus to the brainstem: PHA-L analysis in the rat. J. Comp. Neurol., 1994, 340(1), 11-26. (Pubitemid 24036456)
202. Bowker, R.M.; Westlund, N.; Coulter, J.D. Serotoninergic projections to the spinal cord from the midbrain in the rat: An immunocytochemical and retrograde transport study. Neurosci. Lett., 1981, 24(3), 221-226. (Pubitemid 11001673)
203. Jones, S.L.; Light, A.R. Serotoninergic medullary raphe spinal projection to the lumbar spinal cord in the rat: A retrograde immunohistochemical study. J. Comp. Neurol., 1992, 322(4), 599-610.
204. Maxwell, D.J., Leranth, C.; Verhofstad, A.A. J. Fine structure of serotonin-containing axons in the marginal zone of the rat spinal cord. Brain Res., 1983, 266(2), 253-259.
205. Wessendorf, M.W.; Elde, R. The coexistence of serotonin- and substance P-like immunoreactivity in the spinal cord of the rat as shown by immunofluorescent double labelling. J. Neurosci., 1987, 7(8), 2352-2363.
206. Griffin, L.D.; Mcllon, S.H. Biosynthesis of the neurosteroid 3 alpha-hydroxy-4-pregnene-20-one (3 alpha hp), a specific inhibitor of FSH release. Endocrinology, 2001, 142(11), 4617-4622.
207. Rasmussen, D.D.; Jacobs, W.; Kissinger, P.T.; Malven P.V. Plasma luteinizing hormone in ovariectomized rat following pharmacologic manipulation of endogenous brain serotonin. Brain Res., 1981, 229(1), 230-235.
208. Serri, O.; Chik, C.L.; Ur, E.; Ezzat, S. Diagnosis and management of hyperprolactinemia. CMAJ, 2003, 169(6), 575-581.
209. La Torre, D.; Falorni, A. Pharmacological causes of hyperprolactinemia. Ther. Clin. Risk Manag., 2007, 3(5), 929-951.
210. Samson, W.K.; Taylor, M.M.; Baker, J.R. Prolactin-releasing peptides. Regul. Pept., 2003, 114(1), 1-5.
211. Jøgensen, H.S.; Knigge, U.; Warberg, J. Involvement of 5-HT1, 5-HT2, and 5-HT3 receptors in the mediation of the prolactin response to serotonin and 5-hydroxytryptophan. Neuroendocrinology, 1992, 55(3), 336-343.
212. Jøgensen, H.S. Studies on the neuroendocrine role of serotonin. Dan. Med. Bull., 2007, 54(4), 266-288.
213. Demarest, K.T.; Riegle, G.D.; Moore, K.E. Adenohypophysial dopamine content during physiological changes in prolactin secretion. Endocrinology, 1984, 115(6), 2091-2097.
214. Demarest, K.T.; Riege, GD.; Moore KE. Prolactin-induced activation of tuberoinfundibular dopaminergic neurons: evidence for both a rapid 'tonic' and a delayed 'induction' component. Neuroendocrinology, 1984, 38(6), 467-475.
215. Bosler, C.; Joh, T.H.; Beaudet, A. Ultrastuctural relationship between serotonin and dopamine neurons in the rat arcuate nucleus and medial zone incerta. A combinated radioautographic and immunocytochemical study. Neurosci. Lett:, 1984, 48(3), 279-285. (Pubitemid 14054436)
216. Pilotte, N.S.; Poster, J. Dopamine in hypophysial portal plasma and prolactin in systemic plasma of rat treated with 5-hydroxytriptamine. Endrocrinology, 1981, 108(6), 2137-2141.
217. Ben-Jonathan, N. Dopamine a prolactin inhibitory hormone. Endocr. Rev., 1985, 6(4), 564-589.
218. Willoughby, J.O.; Menadue, M.F.; Liebelt, H. Activation of 5-HT1 serotonin receptors in medial basal hypothalamus stimulates prolactin secretion in the unanesthetized rat. Neuroendocrinology, 1988, 47(1), 83-87. (Pubitemid 18001550)
219. Van der Kar, L.; karteszi, M.; Vetea, C.L.; Ganong, W.F. Serotoninergic stimulation of prolactin and corticosterone secretion is mediated by different pathways from the mediobasal hypothalamus. Neuroendocrinology, 1985, 41(5), 380-384.
220. 1C/2 receptor. Endocrinology, 1993, 133(2), 661-667.
221. Fuxe, K.; Hökfelt, T. Further evidence for the existence of tubero-infundibular dopamine neurons. Acta Physiol. Scand., 1966, 66(1), 245-246.
222. Quattrone, A.; Schettini, G.; di Renzo, G.; Tedeschi, G.; Preziosi, P. Effect of midbrain raphe lesion or 5,7-dihydroxytryptamine treatment of the prolactin-releasing action of quipazine and D-fenfluramine in rats. Brain Res., 1979, 174(1), 71-79.
223. Jagiello-Wójtowicz E.; Zaluska, W., Szponar, J.; Surmaczyńska, B.; Wójcicki, M.; Kleinrok,, Z. Effects of serotonin-active drugs on prolactin secretion in male rats. Pol. J. Pharmacol. Pharm., 1988, 40(1), 73-80. (Pubitemid 18236304)
224. Ficicioǧlu, C.; Tekin, H.I.; Arioǧlu, P.F.; Okar, I. A murine model of adenomyosis: The effects of hyperpolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in wistar albino rats. Acta Eur. Fertil., 1995, 26(2), 75-79.
225. Kiss, J.Z.; Kanycska, B.; Nagy, G.Y. Hypothalamic paraventricular nucleus has a pivotal role in regulation of prolactin release in lacting rats. Endocrinology, 1986, 119(2), 870-873.
226. Mezey, E.; Léránth, C.; Brownstein, M.J.; Friedman, E.; Krieger, D.T.; Palkovits, M. On the origin of the serotonergic input to the intermediate lobe of the rat pituitary. Brain Res., 1984, 294(2), 231-237. (Pubitemid 14194007)
227. Westlund, K.N.; Childs, G.V. Localization of serotonin fibers in the rat adenohypophysis. Endocrinology, 1982, 111(5), 1761-1763.
228. Payette, R.F.; Gershon, M.D.; Nunez, E.A. Serotonergic elements of the mammalian pituitary. Endocrinology, 1985, 116(5), 1933-1942.
229. Linder, A.E.; Ni, W.; Diaz J.L.; Szasz, T.; Burnett, R.; Watts, S.W. Serotonin 5-HT in veins: not all in vain. J. Pharmacol. Exp. Ther., 2007, 323(2), 415-421.
230. Cohen, M.L.; Schenck, K.W.; Hemrick-Luecke, S.H. 5-hydroxytryptamine (1A) receptor activation enhances norepinephrine release from nerves in the rabbit saphenous vein. J. Pharmacol. Exp. Ther., 1999, 290(3), 1195-1201.
231. Blaustein, J.D.; Erskine, M.S. In Hormone Brain and Behavior, Pfaff, D.W.; Arnold, A.P.; Etgen, A.M.; Fahrbach, S.E.; Rubin, R.T. Eds.; Raven Press: New York, 2002, pp. 139-214.
232. Flanagan-Cato, L. M.; Calizo, L.H.; Daniels, D. The synaptic organization of VMH neurons that mediate the effects of estrogens on sexual behaviour. Horm. Behav., 2001, 40(2), 78-82.
233. Hull, E.M.; Dominguez, J.M. Sexual behavior in male rodents. Horm. Behav., 2007, 52(1), 45-55. (Pubitemid 46809862)
234. Marberger, H. In Physiology and Genetics of Reproduction. Coutinho E.M.; Fuchs, F. Eds.; Plenum Press: New York, 1974, pp. 99-110.
235. Davidson J.M. Characteristics of sex behaviour in male rats following castration. Anim. Behav., 1966, 14(2), 266-272.
236. Young, E.A.; Becker, J.B. Perspective: sex matters: gonadal steroids and brain. Neuropsichopharmacology, 2009, 34(3), 537-538.
237. Putnam, S.K.; Sato, S.; Riolo, J.V.; Hull, E.M. Effect of testosterone metabolites on copulation, medial preoptic dopamine, and NOS-immunoreactivity in castrated male rats. Horm. Behav, 2005, 47(5), 531-1522
238. Hamson, D.K.; Jones, B.A.; Watson, N.V. Distribution of androgen receptor immunoreactivity in the brainstem of male rats. Neuroscience, 2004, 127(4), 797-803.
239. Sakuma, Y. Neural substrates for sexual preference and motivation in the female and male rat. Ann. N. Y. Acad. Sci., 2008, 1129, 55-60.
240. Uphouse, L. Female gonadal hormone, serotonin, and sexual receptivity. Brain Res., 2000, 33(2-3), 242-257. (Pubitemid 30697038)
241. Gorzalka, B.B.; Mendelson, S.D.; Watson, N.D. Serotonin receptor subtypes and sexual behaviour. Ann. N. Y. Acad. Sci., 1990, 600, 435-444.
242. Ahlenius, S.; Larsson, K.; Svensson, L. Further evidence for an inhibitory role of central 5-HT in male rat sexual behaviour. Psychopharmacology, 1980, 68(3), 217-220. (Pubitemid 10124214)
243. Verma, S.; Chhina, S.G.; Kumar, V.M.; Singh, B. Inhibition of male sexual behaviour by serotonin application in the medial preoptic area. Physiol. Behav., 1989, 46(2), 327-329.
244. Siddiqui, A.; Niazi, A.; Shaharyar, S.; Wilson, C.A. The 5-HT7 receptor subtype is involved in the regulation of male sexual behaviour in the rat. Pharmacol. Biochem. Behav., 2007, 87(3), 386-392.
245. Okada, R.; Watanabe, H.; Yamanouchi, K.; Arai, Y. Recovery of sexual receptivity in female rats with lesions of ventromedial hypothalamus. Exp. Neurol., 1980, 68(3), 595-600. (Pubitemid 10123869)
246. Pfaff, D.W.; Sakuma, Y. Facilitation of lordosis reflex of female rats from the ventromedial nucleus of the hypothalamus. J. Physiol., 1979, 288, 189-202. (Pubitemid 9146881)
247. Yamamouchi, K.; Arai, Y. Effects of hypothalamic deafferentation on hormonal facilitation of lordosis in ovariectomized rats. Endocrinol. Jpn., 1979, 2(3), 307-312.
248. Luine, V.N.; Frankfurt, M.; Rainbow, T.C., Beigon, A.; Azmitia, E.C. Intrahypothalamic 5,7- dihydroxytryptamine facilitates female sexual behavior and decrease [H3]-imipramine binding and 5-HT uptake. Brain Res., 1983, 264(2) 344-348.
249. Kanno, k.; Shima, S.; Ishida, Y.; Yamanouchi, K. Ipsilateral and contralateral serotoninergic projections from dorsal and media raphe nuclei to the forebrain in rats: Immunofluorescence quantitative analysis. Neurosci. Res., 2008, 61(2), 207-218.
250. Yamanouchi, K.; Nakano, Y.; Arai, Y. Roles of the pontine dorsomedial tegmentum and midbrain central gray in regulating female rat sexual behaviours: Effects of p-chlorophenylalanine. Brain Res. Bull., 1990, 25(3), 381-385.
251. Kishitake, M.; Yamanouchi, K. Facilitatory effects of QAY-100635, a 5-HT1A receptor antagonist, on lordosis in female rats. Neurosci. Lett., 2005, 371(2-3), 147-151. (Pubitemid 39440761)
252. Wilson, C.A. In Pharmacology of Sexual Behaviour, Riley, A.J.; Peetm, M.; Wilson, C.A., Eds.; Oxford University Press: New York, 1993, pp. 1-58.
253. Meyerson, B.J.; Lewander, T. Serotonin synthesis inhibition and estrous behavior in female rats. Life Sci., 1970, 9(12), 661-671.
254. Zemlan, F.P.; Trulson, M.E.; Howell, R.; Hoebel, B.G. Influence of p-chloroamphetamine on female sexual reflexes and brain monoamine levels. Brain Res., 1977, 123(2), 347-356.
255. 2 receptors. Brain Res., 1985, 333(2), 223-229.
256. Wolf, A.; Caldarola-Pastuszka, M.; Uphose, I. Facilitatory of female rat lordosis behavior by hypothalamic infusion of 5-HT(2A/2C) receptor agonists. Brain Res., 1998, 779(1-2), 84-95.
257. Peeters, M.; Giuliano, F. Central neurophysiology and dopaminergic control of ejaculation. Neurosci. Biobehav. Rev., 2008, 32(3), 438-453.
258. Foreman, M.M.; Hall, J.L.; Love, R.L. Effects of fenfluramine and para-chloroamphetamine on sexual behavior of male rats. Psychopharmacology, 1992, 107(2-3), 327-330.
259. Södersten, P.; Berge, O-G; Hole, K. Effects of pchloroamphetamine and 5,7-dyhidroxytriptamine on the sexual behavior of gonadectomized male and female rats. Pharmacol. Biochem. Behav., 1978, 9(4), 499-508.
260. Rényi, L. Ejaculations induced by p-choroamphetamine in the rat. Neuropharmacology, 1985, 24(8), 697-704.
261. Yonezawa, A.; Watanabe, C.; Ando, R.; Furuta, S.; Sakurada, S.; Yoshimura, H.; Iwanaga, T.; Kimura, Y. Characterization of pchoroamphetamine- induce penile erection and ejaculation in anaesthetized rats. Life Sci., 2000, 67(25), 3031-3039.
262. Saito, T.R.; Hokao, R.; Wakafuji, Y.; Igarashi, N.; Agematsu, Y.; Takahashi, K.W. Para-chloroamphetamine (PCA)-induced ejaculation in aged rats, semen analysis and artificial insemination. Lab. Anim., 1996, 30(4), 332-336.
263. Berendnsen, H.H.; Broekkamp, C.L. Drug-induced erections in rats. Indications of serotonin1B receptor mediation. Eur. J. Pharmacol., 1987, 135(3), 279-287.
264. Maeda, N.; Matsuoka, N.; Yamaguchi, I. Possible involvement of the septo-hippocampal cholinergic and raphe-hippocampal serotonergic activations in the penile erection induced by fenfluramine in rats. Brain Res., 1994, 652(2), 181-189. (Pubitemid 24227270)
265. Saito, T.R.; Hokao, R.; Aoki, S.; Wakafugi, Y.; Takahashi, K.W. Effects of p-chloroamphetamine (PCA) on ejaculation in age rats. Jikken Dobutsu., 1993, 42(1), 111-113.
266. Yells, D.P.; Prendergast, M.A.; Hendricks, S.E.; Nakamura, M. Fluoxetine induced inhibition of male rat copulatory behavior: modification by lesions of the nucleus paragigantocelullaris. Pharmacol. Biochem. Behav., 1994, 49(1), 121-127. (Pubitemid 24297266)
267. Frank, J.L.; Hendricks, S.E.; Olson, CH. Multiple ejaculations and chronic fluoxetine: Effects on male rat copulatory behavior. Pharmacol. Biochem. Behav., 2000, 66(2), 337-342.
268. Frye, C.A.; Petralia, S.M.; Rhodas, M.E.; Stein, B. Fluoxetine may influence lordosis of rat through effect on midbrain 3 alpha,5 alpha-THP concentrations. Ann. N. Y. Acad. Sci., 2003, 1007, 37-41. (Pubitemid 38253653)
269. Humphries, C.R.; O'bien, M.; Paxinos, G. PCA: effects of ejaculation, thermoregulation, salivation, and irritability in rats. Pharmacol. Biochem. Beba., 1980, 12(6), 851-854.
270. Matuszczyk, J.V.; Larsson, K.; Eriksson, E. Subchronic administration of fluoxetine impairs estrous behavior in intact female rats. Neuropsychopharmacology, 1998, 19(6), 492-498. (Pubitemid 28491375)
271. Uphouse, L.; Hensler, J.G.; Sarkar, J.; Grossie, B. Fluoxetine disrupts food intake and estrous cyclicity in fischer female rats. Brain Res., 2006, 1072(1), 79-90. (Pubitemid 43255454)
272. Giuliano, F.; Clement, P. Neuroanatomy and physiology of ejaculation. Annu. Rev. Sex Res., 2005, 16, 190-216.
273. Meisel, R.L.; Sachs, B.D. In The Physiology of Reproduction, Knobil, E.; Neill, J.D. Eds.; Raven Press: New York, 1994, Vol.2, pp. 3-105.
274. Allard, J.; Truitt, W.A.; McKenna, K.E.; Coolen, L.M. Spinal cord control of ejaculation. World J. Urol., 2005, 23(2), 119-126.
275. Clark, J.T.; Smith, E.R.; Davidson, J.M. Evidence for the modulation of sexual behavior by alpha-adrenoreceptors in male rats. Neuroendocrinology, 1985, 41(1), 36-43. (Pubitemid 15022918)
276. El-Mallakh, R.S.; Abraham, H.D. MDMA (Ecstasy). Ann. Clin. Psychiatry, 2007, 19(1), 45-52.
277. Tancer, M.; Johanson, C.E. The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethanphetamine(MDMA) in humans. Psychopharmacology, 2007, 189(4), 565-573. (Pubitemid 44791225)
278. Utrilla, P. Aspectos farmacológicos de la anfetaminas. Ars. Pharmaceutica, 2000, 41(1), 67-77.
279. Downing, J. The psychological and physiological effects of MDMA on normal volunters. J. Psychoactive Drugs, 1986, 18(4), 335-340. (Pubitemid 17231265)
280. Harris, D.S.; Baggott, M.; Mendelson, J.H.; Mendelson J.E.; Jones, R.T. Subjective and hormonal effects of 3,4-methylenedioxymenthamphetamine (MDMA) in humans. Psychopharmacology, 2002, 162(4), 396-405. (Pubitemid 35001902)
281. Passie, T.; Hartmann, U.; Schneider, U.; Emrich, H.M.; Krüger, T.H. Ecstasy MDMA mimics the post-orgasmic state: impairment of sexual drive and function during acute MDMA-effects may be due to increased prolactin secretion. Med. Hypotheses, 2005, 64(5), 899-903.
282. McElhatton, P.R.; Bateman, D.N.; Evans, C.; Pughe, K.R.; Thomas, S.H. Congenital anomalies after prenatal ecstasy exposure. Lancet, 1999, 354(9188), 1441-1442.
283. Misra, M.; Papakostas, G.I.; Klibanski, A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J. Clin. Psychiatry, 2004, 65(12), 1607-1618.
284. Meltzer, H.; Bastani, B.; Jayathilake, k.; Maes, M. Fluoxetine but not tricyclic antidepressants, potentiates the 5-hydroxytriptophan-mediated increase in plasma cortisol and prolactin secretion in subjects with major depression or with obsessive compulsive disorder. Neuropharmacology, 1997, 17(1), 1-11.
285. Meston, C.M.; Gorzalka, B.B. Psychoactive drugs and human sexual behaviour: the role of serotonergic activity. J. Psychoactive Drugs, 1992, 24(1), 1-40.
286. Balon, R. Floxetine and sexual dysfunction. JAMA, 1995, 273(19), 1489-1490.
287. Clayton, A.H. Female sexual dysfunction related to depression and antidepressant medications. Curr. Womens Health Rep., 2002, 2(3), 182-187.
288. Kanaly, K.A.; Berman, J.R. Sexual side effects of SSRI medications: potential treatment strategies for SSRI-induced female sexual dysfunction. Curr. Womens Health Rep., 2002, 2(6), 409-416.
289. Quattrone, A.; Di Renzo, G.; Schettini, G.; Tedeschi, G.; Scopacaso, F. Increased plasma prolactin levels induced by dfenfluramine. Relation to central serotonergic stimulation. Eur. J. Pharmacol., 1978, 49(2), 163-167.
290. Lewis, D.A.; Sherman, B.M. Serotonergic regulation of prolactin and growth hormone secretion in man. Acta Endocrinol. (Copen), 1985, 110(2), 152-157.
291. Sessa, B. Is there a case for MDMA-assisted psychotherapy in the UK? J. Psychopharmacol., 2007, 21(2), 220-224.
292. Rappley, M.D. Clinical practice. Attention deficit-hyperactivity disorder. N. Engl. J. Med., 2005, 352(2), 165-173.
293. Findling, R.L. Evolution of the treatment of attention-deficit/ hyperactivity disorder in children: a review. Clin. Ther., 2008, 30(5), 942-957. (Pubitemid 351799870)
294. Mancini, M.C.; Halpern, A. Pharmacological treatment of obesity. Arq. Bras. Endocrinol. Metabol., 2006, 50(2), 377-389.
295. Sharma, A. Anorexia Nervosa and Bulimia Nervosa. Drug Today (Barc.), 2001, 37(4), 229-231.
296. Devlin, M.J.; Goldfein, J.A.; Petkova, E.; Jiang, H.; Raizman, P.S.; Wolk, S.; Mayer, L.; Carino, J.; Bellace, D.; Kamenetz, C.; Dobrow, I.; Walsh, B.T. Cognitive behavioural therapy and fluoxetine as adjuncts to group behavioural therapy for binge eating disorder. Obes. Res., 2005, 13(6), 1077-1088.
297. Grob, C.S.; Poland, R.E.; Chang, L.; Ernst, T. Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Brain Res., 1996, 73(1-2), 103-107.
298. Mas, M.; Farré, M.; de la Torre, R.; Roset, P.N.; Ortuño, J.; Segura, J.; Camí, J. Cardiovascular and neuroendocrine effects and pharmakokinetics of 3,4-methylenedyoxymethamphetamine in humans. J. Pharmacol. Exp. Ther., 1999, 290(1), 136-145.
299. Guerra, G.; Zaimovic, A.; Ferri, M.; Zambelli, U.; Timpano, M.; Neri, E.; Marzocchi, G.F.; Delsignore, R.; Brambilla, F. Longlasting effects of (+/-)3,4-methylenedioxymethamphetamine (ecstasy) on serotonin system function in humans. Biol. Psychiatr., 2000, 47(2), 127-136. (Pubitemid 30069736)
300. Coccaro, E.F.; Kavoussi, M.D.; Cooper, T.B.; Hauger, R.L. Hormonal responses to d- and dl-fenfluramine in healthy human subjects. Neuropsychopharmacology, 1996, 15(6), 595-607. (Pubitemid 26400764)
301. Gorard, D.A.; Taylor, T.M.; Medbak, S.H.; Perry, L.A.; Libby, G.W.; Farthing, M.J. Plasma prolactin, adrenocorticotropin hormone and cortisol after administration of D-fenfluramine or placebo to healthy subjects. Int. Clin. Psychopharmacol., 1993, 8(2), 123-128.
302. Mitchell, P.B.; Smythe, G.A. Endocrine and amine responses to D,L-Fenfluramine in normal subjects. Psychiatry Res., 1991, 39(2), 141-153.
303. Monteleone, P.; La Rocca, A.; Fuschino, A.; Bortolotti, F.; Maj, M. Seasonal variation in plasma prolactin response to d-fenfluramine in healthy subjects. Psychoneuroendocrinology, 1999, 24(2), 201-208. (Pubitemid 29125351)
304. Rajewska, J.; Rybakowski, J.K. Depression in premenopausal women, gonadal hormones and serotonergic system assessed by D-fenfluramine challenge test. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2003, 27(4), 705-709.
305. Lichtenberg, P.; Shapira, B.; Gillon, D.; Kindler, S.; Cooper, T.B.; Newman, M.E.; Lerer, B. Hormone response to fenfluramine and placebo challenge in endogenous depression. Psychiatry Res., 1992, 43(2), 137-146.
306. Mitchell, P.; Smythe, G. Hormonal responses to fenfluramine in depressed and control subjects. J. Affect. Disord., 1990, 19(1), 43-51. (Pubitemid 20141160)
307. Myers, J.E.; Buysse, D.J.; Thase, M.E.; Perel, J.; Miewald, J.M.; Cooper, T.B.; Kupfer, D.J.; Mann, J. The effects of fenfluramine on sleep and prolactin in depressed inpatients: A comparison of potential indices of brain serotonergic responsivity. Biol. Psychiatry, 1993, 34(11), 753-758.
308. Shapira, B.; Reiss, A.; Kaiser, N.; Kindler, S.; Lerer, B. Effect of imipramine treatment on the prolactine response to fenfluramine and placebo challenge in depressant patients. J. Affect. Disord., 1989, 16(1), 1-4. (Pubitemid 19020848)
309. Siever, L.J.; Murphy, D.L.; Slater, S.; de La Vega, E.; Lipper, S. Plasma prolactin changes following fenfluramine in depressed patients compared to controls: An evaluation of central serotonergic responsivity in depression. Life Sci., 1984, 34(11), 1029-1039.
310. Peterson, M.C. Reversible galactorrhea and prolactin elevation related to fluoxetine use. Mayo Clin. Proc., 2001, 76(2), 215-216.
311. Papakostas, G.I.; Miller, K.K.; Petersen, T.; Skarsky, K.G.; Hilliker, S.E.; Klibanski, A.; Fava, M. Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. J. Clin. Psychiatry, 2006, 67(6), 952-957. (Pubitemid 44049094)
312. Csoka, A.; Bahrick, A.; Mehtonen, O.P. Persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors. J. Sex. Med., 2008, 5(1), 227-233.
313. Labbate, L.A.; Grimes, J.; Hines, A.; Oleshansky, M.A.; Arana, G.W. Sexual dysfunction induced by serotonin reuptake antidepressants. Sex Marital Ther., 1998, 24(1), 3-12. (Pubitemid 28049559)
314. Lane, R.M. A critical review of selective serotonin reuptake inhibitor-related sexual dysfunction, incidence, possible aetiology and implications for management. J. Psychopharmacol., 1997, 11(1), 72-82.
315. Montej-González, A.L.; Llorca, G.; Izquierdo, J.A.; Ledesma, A.; Bousoño, M.; Calcedo, A.; Carrasco, J.L.; Ciudad, J.; Daniel, E.; De la Gandara, J.; Derecho, J; Franco, M.; Gomez, M.J.; Macias, J.A.; Martin, T.; Perez, V.; Sanchez, J.M.; Sanchez, S.; Vicens, E. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline and fluvoxamine in a propspective, multicenter and descriptive clinical study of 344 patients. Sex Marital Ther., 1997, 23(3), 176-194.
316. Seidman, S. Ejaculatory dysfunction and depression: pharmacological and psychobiological interactions. Int. J. Impot. Res., 2006, 18(1), S33-S38. (Pubitemid 44330310)
317. Stimmel, G.L.; Gutierrez, M.A. Sexual dysfunction and psychotropic medications. CNS Spectr., 2006, 11(8), 24-30.
318. Buffum, J.; Moser, C. MDMA and human sexual function. J. Psychoactive Drugs, 1986, 18(4), 355-359.
319. Zemishlany, Z.; Aizenberg, D.; Weizman, A. Subjective effects of MDMA ("Ecstasy") on human sexual function. Eur. Psychiatry, 2001, 16(2), 127-130. (Pubitemid 32233917)
320. Bang-Ping, J. Sexual Dysfunction in men who abuse illicit drugs: A preliminary report. J. Sex. Med., 2009, 6(4), 1072-1080.
321. Balon, R. Intermittent amantadine for fluoxetine-induced anorgasmia. Sex Marital Ther., 1996, 2(4), 290-292.
322. Hermana, J.B.; Brotman, A.W.; Pollack, M.H.; Falk, W.E.; Bioderman, J.; Rosenbaum, J.F. Fluoxetine-induced sexual dysfunction. J. Clin. Psychiatry, 1990, 51(1), 25-27.
323. Balon, R. Fluoxetien-induced sexual dysfunction and yohimbine. J. Clin. Psychiatry, 1993, 54(4), 161-162. (Pubitemid 23141522)
324. Shen, W.W.; Hsu; J.H. Female sexual side effects associated with selective serotonin reuptake inhibitors: a descriptive clinical study of 33 patients. Int. J. Psychiatry Med., 1995, 25(3), 239-248.
325. Hines, R.N.; Adams, J.; Buck, G.M.; Faber, W.; Holson, J.F.; Jacobson, S.W. ; Keszler, M.; McMartin, K.; Segraves, R.T.; Singer, L.T.; Sipes, I.G.; Williams, P.L. NTP-CERHR Expert panel report on the reproductive and developmental toxicity of fluoxetine. Birth Defects Res. B Dev. Reprod. Toxicol., 2004, 71(4), 193-280.
326. Kara, H.; Aydin, S.; Yũcel, M.; Agargũn, M.Y.; Odabaş, O.; Yilmaz, Y. The efficacy of fluoxetine in the treatment of premature ejaculation: A double-blind placebo controlled study. J. Urol., 1996, 156(5), 1631-1632. (Pubitemid 26344007)
327. Kim, S.C.; Seo, K.K. Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: A double-blind placebo controlled study. J. Urol., 1998, 159(2), 425-427. (Pubitemid 28049248)
328. Modell, J.G.; Katholi, C. R.; Modell, J. D.; DePalma, R.L. Comparative sexual side effects of bupropion, fluoxetine, paroxetine and sertraline. Clin. Pharmacol. Ther., 1997, 61(4), 476-487.
329. Clayton, A.H.; Warnock, J.K.; Kornstein, SG.; Pinkerton, R.; Sheldon-Keller, A.; McGarvey, E.L. A placebo-controlled trial of buspiron SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J. Clin. Psychiatry, 2004, 65, 62-67.
330. Cohen, P.G.; Holbrook, J.M. Effects of fenfluramine on ejaculatory function, luteinizing hormone and testosterone levels in men with hypogonadotropic hypogonadism and premature ejaculation. Int. Clin. Psychopharmacol., 1999, 14(2), 91-94.
331. Pfaff, D. W.; Vasudevan, N.; Attardi, B. In Neuroendocrinology in Physiology and Medicine, Conn, P.M.; Freeman, M.E. Eds.; Humana Press: New Jersey, 2000, pp. 287-300.
332. Afonso, V.M.; Lehmann, H.; Tse, M.; Woehrling, A.; Pfaus, J.G. Estrogen and the neural mediation of female-male mounting in the rat. Behav. Neurosci., 2009, 123(2), 369-381.
333. White, S.; Uphose, L. Estrogen and progesterone dose-dependently reduce disruptive effects of restraint on lordosis behavior. Horm. Behav., 2004, 45(3), 201-208.
334. Hart, B.L.; Leedy, M.G. In Handbook of Behavioral Neurobiology, Adler, N.; Pfaff, D.; Goy, R.W. Eds.; Plenum Press: New York, 1985, Vol.7, pp. 3-45.
335. Buvat, J.; Lemaire, A.; Buvat-Herbaut, M.; Fourlinnie, J.C.; Racadot, A.; Fossati, P. Hyperprolactinemia and sexual function in men. Horm. Res., 1985, 22(3), 196-203.